Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PDS Biotechnology Corp Director's Dealing 2023

Jan 6, 2023

34613_dirs_2023-01-06_5f4b1e55-d75d-4f38-96bc-fdb71a83cb22.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PDS Biotechnology Corp (PDSB)
CIK: 0001472091
Period of Report: 2023-01-05

Reporting Person: WOOD LAUREN (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-01-05 Employee Stock Option (Right to Buy) $11.61 A 110800 Acquired 2033-01-05 Common Stock (110800) Direct

Footnotes

F1: This option, representing a right to purchase a total of 110,800 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027.